Government-Owned Inventions; Availability for Licensing, 20929-20930 [E8-8218]

Download as PDF Federal Register / Vol. 73, No. 75 / Thursday, April 17, 2008 / Notices 2008 (HHS Reference No. E–003–2007/ 0–US–01). Licensing Status: Available for exclusive and non-exclusive license. Licensing Contact: Richard Rodriguez; 301–435–4013; rodrigr@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Center for Cancer Research Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize nanoantibodies as therapeutics or diagnostics including imaging agents. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. sroberts on PROD1PC64 with NOTICES Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer Description of Technology: The technology relates to the use of cDNA microarrays to facilitate the identification of pulmonary neuroendocrine tumors. In order to identify molecular markers that could be used to classify pulmonary tumors, the inventors examined the gene expression profiles of clinical samples from patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), and typical carcinoma (TC) tumors by cDNA microarray analysis to detect hybridization between cDNA from tumor cells and DNA from a panel of 8,897 human genes. Gene expression was found to be nonrandom and to exhibit highly significant clustering that divided the tumors into their assigned World Health Organization (WHO) classification with 100% accuracy. The inventors concluded that pulmonary neuroendocrine tumors could be classified based on the genome-wide expression profile of the clinical samples without further manipulations. Applications: Method to differentiate three types of pulmonary neuroendocrine tumors; Method to diagnose pulmonary neuroendocrine cancer; Neuroendocrine Microarray Advantages: Accurate, rapid, easy to use diagnostic to stratify patients according to pulmonary tumors Development Status: The technology is currently in the pre-clinical stage of development. Market: An estimated 1,444,920 new cancer diagnoses in the U.S. in 2007. Cancer is the second leading cause of death in United States. It is estimated that the cancer therapeutic market would double to $50 VerDate Aug<31>2005 17:08 Apr 16, 2008 Jkt 214001 billion a year in 2010 from $25 billion in 2006. Inventors: Curtis C. Harris et al. (NCI). Relevant Publications: P He et al. Identification of carboxypeptidase E and g-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Human Pathol. 2004 Oct;35(10):1196–1209. Patent Status: U.S. Patent Application No. 10/533,459 filed 02 May 2005 (HHS Reference No. E–248–2002/0–US–04). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Jennifer Wong; 301–435–4633; wongje@mail.nih.gov Dated: April 8, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–8213 Filed 4–16–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Substituted 3,6-diphenyl-7H-[1,2,4] triazolo[3,4-b] [1,3,4] Thiadiazines as Potent Inhibitors of PDE4A, PDE4B, and PDE4D Description of Technology: Phosphodiesterase 4 (PDE4) is a major cAMP-metabolizing enzyme found in immune and inflammatory cells, airway PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 20929 smooth muscle, and pulmonary nerves. It plays a significant role within the inflammatory responses associated with asthma and chronic obstructive pulmonary disease (COPD) and its modulation has been linked to memory enhancement and depression. Due to its widespread therapeutic potential, PDE4 inhibitors are highly sought after agents for treating numerous disease states. While several PDE4 inhibitors have already advanced into clinical settings, unfavorable side effects including emesis, nausea, and abdominal pain emphasize the need for novel chemotypes with potent and selective PDE4 inhibition. This technology describes a series of substituted 3,6-diphenyl-7H-[1,2,4] triazolo[3,4-b] [1,3,4] thiadiazines that act as inhibitors of PDE4. This core structure represents a novel chemotype within extensive classes of PDE4 inhibitors and the structure activity relationships of these PDE4 inhibitors identify key binding sites and substitutions critical to the functionality for potent PDE4 inhibition. Selectivity of this novel chemotype shows weak inhibitory potency against nine PDE isoforms excluding PDE4 and strong inhibitory potency against PDE4A, PDE4B, and PDE4D. In a selectivity comparison study, the novel chemotype performs better than the PDE4 inhibitor in clinical development. Subtypeselective PDE4 inhibitors are becoming increasingly more important as new research shows that independent PDE isoforms have differential effects on cells. Applications: Treatment of numerous diseases associated with PDE4 including asthma, COPD, inflammatory bowel disease, and other anti-inflammatory diseases with other possible treatments including depression and psychosis. Development Status: Pre-clinical. Publication: AP Skoumbourdis et al. Identification of a potent new chemotype for the selective inhibition of PDE4. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1297–1303. Inventors: Craig J. Thomas et al. (NHGRI). Patent Status: U.S. Provisional Application No. 61/020,079 filed 09 Jan 2008 (HHS Reference No. E–055–2008/ 0–US–01). Licensing Status: Available for licensing. Licensing Contact: Fatima Sayyid, M.H.P.M.; 301–435–4521; Fatima.Sayyid@nih.hhs.gov. E:\FR\FM\17APN1.SGM 17APN1 20930 Federal Register / Vol. 73, No. 75 / Thursday, April 17, 2008 / Notices sroberts on PROD1PC64 with NOTICES Nitrite and Nitrite-Methemoglobin Therapy To Detoxify Stroma-Free Hemoglobin Based Blood Substitutes Description of Technology: Cell-free hemoglobin based oxygen carriers (HBOCs) are blood substitutes and resuscitative agents that can be used to replace whole blood donations, alleviate blood shortages and reduce the risks of infections such as HIV and hepatitis. Stroma-free HBOCs offer the advantages of increased stability, consistency of supply, and reduced immunogenicity over the use of the alternative cell based sources. However, the side effects associated with their use, including vascular toxicity, pulmonary and systemic hypertension, myocardial infarction, inflammation, and platelet aggregation severely limit their scope of clinical applications. These adverse effects are due in part to the ability of free deoxygenated hemoglobin (deoxyHb) to scavenge for nitric oxide (NO) thus rendering it unavailable for vasodilating blood vessels. This technology is a method of using nitrites to reduce the deleterious effects associated with HBOC use as blood substitutes. Free nitrites or nitritemethemoglobin when added to stromafree HBOCs are converted to NO and N2O3 which escapes the scavenging activity of deoxyHb and thus is free to vasodilate blood vessels. This maintains oxygen release and NO delivery enabling improved clinical outcomes. Recent studies, using this technology as a blood substitute, have led to a reversal of vasoconstriction, hypertension and hemorrhagic shock in animal models. This new approach also reduces the toxicity associated with the use of HBOCs as a blood substitute and may allow the widespread use of HBOCs as an alternative to cell based sources. In combination with this technology, HBOC blood substitutes may now be used to efficiently deliver therapeutic agents and maintain organ perfusion during trauma and surgery. Advantages: Reduced toxicity of cell free hemoglobin blood substitutes; Increased blood perfusion in patients; Decreased dependence on blood donations. Development Status: Pre-clinical. Inventors: Mark T. Gladwin (NHLBI) et al. Publication: S Basu, R Grubina, J Huang, J Conradie, Z Huang, A Jeffers, A Jiang, X He, I Azarov, R Seibert, A Mehta, R Patel, SB King, N Hogg, A Ghosh, MT Gladwin, DB Kim-Shapiro. Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol. 2007 Dec;3(12):785–794. VerDate Aug<31>2005 18:11 Apr 16, 2008 Jkt 214001 Patent Status: U.S. Provisional Application No. 60/996,530 filed 31 Aug 2007 (HHS Reference No. E–259– 2007/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Fatima Sayyid, M.H.P.M.; 301–435–4521; Fatima.Sayyid@nih.hhs.gov. Dated: April 8, 2008. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–8218 Filed 4–16–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Meeting Notice is hereby given of a meeting of the Services Subcommittee of the Interagency Autism Coordinating Committee (IACC). The purpose of the Services Subcommittee is to review the current state of services and supports for individuals with Autism Spectrum Disorder (ASD) and their families in order to improve these services. The Subcommittee meeting will be closed to the public with attendance limited to IACC members. The Subcommittee will report on its meeting at the next meeting of the IACC on May 12, 2008. Name of Committee: Interagency Autism Coordinating Committee (IACC). Type of meeting: Services Subcommittee. Date: April 30, 2008. Time: 1 p.m. to 3 p.m. Agenda: Review the current state of services and supports for individuals with ASD and their families. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Bethesda, MD 20892–9669. (Telephone Conference Call) Contact Person: Tanya Pryor, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6198, Bethesda, MD 20892– 9669, 301–443–7153, pryort@mail.nih.gov. Information about the IACC is available on the Web site: http://www.nimh.nih.gov/ research-funding/scientific-meetings/ recurring-meetings/iacc/index.shtml. Dated: April 8, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–8226 Filed 4–16–08; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5187–N–20] Renewal Communities Annual Progress Reporting Office of the Chief Information Officer, HUD. ACTION: Notice. AGENCY: SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. Renewal Communities are required to submit annual reports to HUD on the progress of their Tax Incentive Utilization Plan in assisting State and local governments and communitybased organizations in their outreach to the business community and residents. DATES: Comments Due Date: May 19, 2008. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2506–0173) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202–395–6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail Lillian Deitzer at Lillian_L_Deitzer@HUD.gov or telephone (202) 402–8048. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Deitzer. SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the E:\FR\FM\17APN1.SGM 17APN1

Agencies

[Federal Register Volume 73, Number 75 (Thursday, April 17, 2008)]
[Notices]
[Pages 20929-20930]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8218]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Substituted 3,6-diphenyl-7H-[1,2,4] triazolo[3,4-b] [1,3,4] 
Thiadiazines as Potent Inhibitors of PDE4A, PDE4B, and PDE4D

    Description of Technology: Phosphodiesterase 4 (PDE4) is a major 
cAMP-metabolizing enzyme found in immune and inflammatory cells, airway 
smooth muscle, and pulmonary nerves. It plays a significant role within 
the inflammatory responses associated with asthma and chronic 
obstructive pulmonary disease (COPD) and its modulation has been linked 
to memory enhancement and depression. Due to its widespread therapeutic 
potential, PDE4 inhibitors are highly sought after agents for treating 
numerous disease states. While several PDE4 inhibitors have already 
advanced into clinical settings, unfavorable side effects including 
emesis, nausea, and abdominal pain emphasize the need for novel 
chemotypes with potent and selective PDE4 inhibition.
    This technology describes a series of substituted 3,6-diphenyl-7H-
[1,2,4] triazolo[3,4-b] [1,3,4] thiadiazines that act as inhibitors of 
PDE4. This core structure represents a novel chemotype within extensive 
classes of PDE4 inhibitors and the structure activity relationships of 
these PDE4 inhibitors identify key binding sites and substitutions 
critical to the functionality for potent PDE4 inhibition. Selectivity 
of this novel chemotype shows weak inhibitory potency against nine PDE 
isoforms excluding PDE4 and strong inhibitory potency against PDE4A, 
PDE4B, and PDE4D. In a selectivity comparison study, the novel 
chemotype performs better than the PDE4 inhibitor in clinical 
development. Subtype-selective PDE4 inhibitors are becoming 
increasingly more important as new research shows that independent PDE 
isoforms have differential effects on cells.
    Applications: Treatment of numerous diseases associated with PDE4 
including asthma, COPD, inflammatory bowel disease, and other anti-
inflammatory diseases with other possible treatments including 
depression and psychosis.
    Development Status: Pre-clinical.
    Publication: AP Skoumbourdis et al. Identification of a potent new 
chemotype for the selective inhibition of PDE4. Bioorg Med Chem Lett. 
2008 Feb 15;18(4):1297-1303.
    Inventors: Craig J. Thomas et al. (NHGRI).
    Patent Status: U.S. Provisional Application No. 61/020,079 filed 09 
Jan 2008 (HHS Reference No. E-055-2008/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521; 
Fatima.Sayyid@nih.hhs.gov.

[[Page 20930]]

Nitrite and Nitrite-Methemoglobin Therapy To Detoxify Stroma-Free 
Hemoglobin Based Blood Substitutes

    Description of Technology: Cell-free hemoglobin based oxygen 
carriers (HBOCs) are blood substitutes and resuscitative agents that 
can be used to replace whole blood donations, alleviate blood shortages 
and reduce the risks of infections such as HIV and hepatitis. Stroma-
free HBOCs offer the advantages of increased stability, consistency of 
supply, and reduced immunogenicity over the use of the alternative cell 
based sources. However, the side effects associated with their use, 
including vascular toxicity, pulmonary and systemic hypertension, 
myocardial infarction, inflammation, and platelet aggregation severely 
limit their scope of clinical applications. These adverse effects are 
due in part to the ability of free deoxygenated hemoglobin (deoxyHb) to 
scavenge for nitric oxide (NO) thus rendering it unavailable for 
vasodilating blood vessels.
    This technology is a method of using nitrites to reduce the 
deleterious effects associated with HBOC use as blood substitutes. Free 
nitrites or nitrite-methemoglobin when added to stroma-free HBOCs are 
converted to NO and N2O3 which escapes the scavenging activity of 
deoxyHb and thus is free to vasodilate blood vessels. This maintains 
oxygen release and NO delivery enabling improved clinical outcomes. 
Recent studies, using this technology as a blood substitute, have led 
to a reversal of vasoconstriction, hypertension and hemorrhagic shock 
in animal models. This new approach also reduces the toxicity 
associated with the use of HBOCs as a blood substitute and may allow 
the widespread use of HBOCs as an alternative to cell based sources. In 
combination with this technology, HBOC blood substitutes may now be 
used to efficiently deliver therapeutic agents and maintain organ 
perfusion during trauma and surgery.
    Advantages: Reduced toxicity of cell free hemoglobin blood 
substitutes; Increased blood perfusion in patients; Decreased 
dependence on blood donations.
    Development Status: Pre-clinical.
    Inventors: Mark T. Gladwin (NHLBI) et al.
    Publication: S Basu, R Grubina, J Huang, J Conradie, Z Huang, A 
Jeffers, A Jiang, X He, I Azarov, R Seibert, A Mehta, R Patel, SB King, 
N Hogg, A Ghosh, MT Gladwin, DB Kim-Shapiro. Catalytic generation of 
N2O3 by the concerted nitrite reductase and anhydrase activity of 
hemoglobin. Nat Chem Biol. 2007 Dec;3(12):785-794.
    Patent Status: U.S. Provisional Application No. 60/996,530 filed 31 
Aug 2007 (HHS Reference No. E-259-2007/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521; 
Fatima.Sayyid@nih.hhs.gov.

    Dated: April 8, 2008.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E8-8218 Filed 4-16-08; 8:45 am]
BILLING CODE 4140-01-P